MycophenolateMofetil

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia

In the September 2, 2021 article of the New England Journal of Medicine Charlotte Bardbury and colleagues report on the results of mycophenolate mofetil for first-line treatment of immune thrombocytopenia Background: ITP is a rare autoimmune disorder leading to not only excessive bleeding and bruising but fatigue as well. Steroids are first-line treatment but are […]

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia Read More »

breast cancer

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

In the August 20, 2021 addition of JCO Nancy Lin and colleagues published on the results of pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER-2/neu positive metastatic breast cancer. Given the paucity of efficacious therapies in this patient population, investigators wanted to test the hypothesis that there is a dose-dependent response

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Read More »

breast cancer

Comparison of Radiation with or without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma in situ Resected by Lumpectomy: A Phase III Clinical Trial

In the July 20, 2021 edition of Journal of Clinical Oncology, Melody Cobleigh and colleagues report on the results of a phase III trial of radiation with or without concurrent trastuzumab for Her2 positive ductal carcinoma in situ. PURPOSE The primary aim of the B-43 study was to evaluate the utility and efficacy of radiotherapy

Comparison of Radiation with or without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma in situ Resected by Lumpectomy: A Phase III Clinical Trial Read More »

lung cancer

Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%

In the July 20, 2021 edition of Journal of Clinical Oncology, Martin Reck and colleagues report on the 5-year results of pembrolizumab versus chemotherapy in metastatic non-small cell lung cancer. PURPOSE The investigators report on the 5-year follow-up of any 1st-line phase 3 immunotherapy trial for NSCLC. KEYNOTE-024 is a randomized, open-label, controlled trial of

Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50% Read More »

trastuzumab

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

In the July 20, 2021 edition of Journal of Clinical Oncology, Sara Tolaney and colleagues report on the results of the ATEMPT trial. PURPOSE The purpose of the ATEMPT trial was to determine if treatment with trastuzumab emtansine (T-DM1) causes less toxicity compared to paclitaxel plus trastuzumab (TH) while delivering acceptable invasive disease-free survival (iDFS)

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial Read More »

radiotherapy

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

In the July 10, 2021 edition of Journal of Clinical Oncology, Derya Tilki and colleagues report on the results of a trial of early salvage radiotherapy in men with high-risk prostate cancer PURPOSE The purpose of the study was to compare early salvage radiation therapy (sRT) following radical prostatectomy (RP) in men with adverse pathologic

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death Read More »

Lenvatinib

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

In the July 10, 2021 edition of Journal of Clinical Oncology, Jaume Capdevila and colleagues report on the results of the TALENT (GETNE 1509) trial PURPOSE The purpose of the study was to investigate the efficacy and safety of lenvatinib in patients with previously treated advanced gastroentero-pancreatic-neuroendocrine tumor PATIENTS AND METHODS The study was a

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) Read More »

adcetris-brentuximab-vedotin--

Brentuximab Vedotin Combined with Chemotherapy in Patients with Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

Brentuximab Vedotin Combined with Chemotherapy in Patients with Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma In the July 10, 2021 edition of Journal of Clinical Oncology, Anita Kumar and colleagues report on the results of brentuximab vedotin combined with chemotherapy in newly diagnosed early-stage, unfavorable-risk hodgkin lymphoma PURPOSE The purpose of the study was to determine

Brentuximab Vedotin Combined with Chemotherapy in Patients with Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma Read More »

Bladder Cancer

No Benefit to the Addition of Pembrolizumab to Chemotherapy in Advanced Urothelial Carcinoma

In the July 1, 2021 edition of Lancet Oncology, investigators reported on the lack of benefit to the addition of pembrolizumab to chemotherapy in Advanced Urothelial Carcinoma. Purpose The investigators wanted to determine the utility of the addition of pembrolizumab to standard chemotherapy regimen of gemcitabine 1000 mg/m² plus carboplatinum concurrent with pembrolizumab. Methods KEYNOTE 361 was an open label, randomized phase 3

No Benefit to the Addition of Pembrolizumab to Chemotherapy in Advanced Urothelial Carcinoma Read More »

en_USEnglish